Edition:
United Kingdom

Dr.Reddy's Laboratories Ltd (REDY.NS)

REDY.NS on National Stock Exchange of India

2,438.25INR
9:20am GMT
Change (% chg)

Rs0.20 (+0.01%)
Prev Close
Rs2,438.05
Open
Rs2,449.90
Day's High
Rs2,470.00
Day's Low
Rs2,406.80
Volume
362,260
Avg. Vol
943,930
52-wk High
Rs2,670.80
52-wk Low
Rs1,887.00

Latest Key Developments (Source: Significant Developments)

Dr.Reddy's Laboratories Says Regulatory Authority Of Germany Concluded Follow-On Audit Of Co's Duvvada Facility
Monday, 12 Nov 2018 

Nov 12 (Reuters) - Dr.Reddy's Laboratories Ltd ::ON NOV 9, REGULATORY AUTHORITY OF GERMANY CONCLUDED FOLLOW-ON AUDIT OF CO'S FORMULATIONS MANUFACTURING FACILITY IN DUVVADA.FACILITY IS CONSIDERED COMPLIANT & EU-GMP CERTIFICATION CONTINUES TO REMAIN ACTIVE WITH 1 SPECIFIC EXCLUSION OF A NEW PRODUCT.SAYS CO WILL BE SUBMITTING A DETAILED CORRECTIVE AND PREVENTIVE ACTION PLAN (CAPA) TO AUTHORITIES.  Full Article

Dr.Reddy's Labs Launches Atomoxetine Capsules, USP In U.S. Market
Wednesday, 31 Oct 2018 

Oct 31 (Reuters) - Dr.Reddy's Laboratories Ltd ::SAYS LAUNCH OF ATOMOXETINE CAPSULES, USP IN THE U.S. MARKET.  Full Article

India's Dr.Reddy's Laboratories Sept-Qtr Consol Profit Up About 70 Pct
Friday, 26 Oct 2018 

Oct 26 (Reuters) - Dr.Reddy's Laboratories Ltd ::SEPT QUARTER CONSOL PAT 5.20 BILLION RUPEES - TV.CONSENSUS FORECAST FOR SEPT QUARTER CONSOL PROFIT WAS 3.52 BILLION RUPEES.SEPT QUARTER CONSOL NET PROFIT 5.18 BILLION RUPEES VERSUS PROFIT OF 3.05 BILLION RUPEES LAST YEAR.SEPT QUARTER CONSOL NET SALES 36.87 BILLION RUPEES VERSUS 34.91 BILLION RUPEES LAST YEAR.THE FIRST PROFIT ALERT WAS SOURCED FROM TELEVISION.  Full Article

Dr.Reddy's Laboratories Launches Colesevelam Hydrochloride Tablets In U.S.
Tuesday, 9 Oct 2018 

Oct 9 (Reuters) - Dr.Reddy's Laboratories Ltd ::LAUNCHES COLESEVELAM HYDROCHLORIDE TABLETS IN THE U.S. MARKET.  Full Article

Dr. Reddy's Laboratories Announces That It Has Regained Worldwide Rights to DFA-02
Monday, 1 Oct 2018 

Oct 1 (Reuters) - Dr.Reddy's Laboratories Ltd ::DR. REDDY'S LABORATORIES ANNOUNCES THAT IT HAS REGAINED WORLDWIDE RIGHTS TO DFA-02.DR.REDDY'S LABORATORIES - TERMINATION OF LICENSE GRANTED TO ARMIS BIOPHARMA FOR INVESTIGATIONAL ANTIBACTERIAL PRODUCT, DFA-02.  Full Article

Dr. Reddy's Laboratories Announces Sale Of Its Antibiotic Manufacturing Site
Monday, 1 Oct 2018 

Oct 1 (Reuters) - Dr.Reddy's Laboratories Ltd ::PRESS RELEASE - DR. REDDY'S LABORATORIES ANNOUNCES THE SALE OF ITS ANTIBIOTIC MANUFACTURING SITE AND ITS RELATED ASSETS IN BRISTOL, TENNESSEE.DR.REDDY'S LABORATORIES LTD - SEPARATE 24,000-SQUARE-FOOT PLASTICS-PROCESSING FACILITY IN BRISTOL IS ALSO INCLUDED IN DEAL.DR.REDDY'S LABORATORIES - SOLD ISSUED & OUTSTANDING MEMBERSHIP INTERESTS IN DR. REDDY'S LABORATORIES TENNESSEE, LLC & SOME RELATED ASSETS.  Full Article

Dr.Reddy's Laboratories Announces Launch Of Imatinib Mesylate Tablets In U.S. Market
Monday, 1 Oct 2018 

Oct 1 (Reuters) - Dr.Reddy's Laboratories Ltd ::SAYS LAUNCH OF IMATINIB MESYLATE TABLETS, USP IN U.S. MARKET.  Full Article

Dr. Reddy's Laboratories Announces The Launch Of Neostigmine Methylsulfate Injection, Usp In The U.S. Market
Wednesday, 12 Sep 2018 

Sept 12 (Reuters) - Dr.Reddy's Laboratories Ltd ::DR. REDDY'S LABORATORIES ANNOUNCES THE LAUNCH OF NEOSTIGMINE METHYLSULFATE INJECTION, USP IN THE U.S. MARKET.DR.REDDY'S LABORATORIES LTD - DR. REDDY'S NEOSTIGMINE METHYLSULFATE INJECTION, USP IS AVAILABLE IN 5 MG/10 ML AND 10 MG/10 ML MULTI-DOSE VIALS.  Full Article

Dr. Reddy's Laboratories Announces Launch Of Neostigmine Methylsulfate Injection, USP In U.S. Market
Wednesday, 12 Sep 2018 

Sept 12 (Reuters) - Dr.Reddy's Laboratories Ltd ::ANNOUNCES LAUNCH OF NEOSTIGMINE METHYLSULFATE INJECTION, USP IN U.S. MARKET.  Full Article

India's Dr.Reddy's Laboratories June-Qtr Consol Net Profit After Tax Rises Over 7-fold
Thursday, 26 Jul 2018 

July 26 (Reuters) - Dr.Reddy's Laboratories Ltd ::JUNE QUARTER CONSOL NET PROFIT AFTER TAX 4.76 BILLION RUPEES VERSUS PROFIT OF 666 MILLION RUPEES LAST YEAR.CONSENSUS FORECAST FOR JUNE QUARTER CONSOL NET PROFIT WAS 2.98 BILLION RUPEES.JUNE QUARTER CONSOL NET SALES 36.51 BILLION RUPEES VERSUS 32.49 BILLION RUPEES LAST YEAR.  Full Article

UPDATE 2-Cost cuts help drugmaker Indivior as it battles cheap rival

* Shares give back early gains to trade lower (Adds details on the company's drugs, background, comments)